Radiation-induced gliomas

Expert Review of Neurotherapeutics

Volumn 9, Issue 10, 2009, Pages 1511-1517

  Prasad, Gautam ^a   Haas Kogan, Daphne A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastoma; Gliomas; Pediatric neuro oncology; Radiation; Secondary malignancy

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PROTEIN P16; PROTEIN P53; TEMOZOLOMIDE; TRANSCRIPTION FACTOR SOX10;

ACUTE LYMPHOBLASTIC LEUKEMIA; ASTROCYTOMA; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DOSIMETRY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC DIFFERENCE; GLIOBLASTOMA; GLIOMA; HUMAN; IONIZING RADIATION; LEUKEMIA; MENINGIOMA; METASTASIS; MOLECULAR GENETICS; MTAP GENE; NEUROEPITHELIOMA; NEUROTOXICITY; OCCUPATIONAL EXPOSURE; ONCOGENE; PROSTATE CANCER; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INDUCED GLIOMA; REVIEW; RISK ASSESSMENT; TINEA CAPITIS; UTERINE CERVIX CANCER;

BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GLIOMA; HUMANS; INCIDENCE; MALE; NEOPLASMS, RADIATION-INDUCED; RADIATION; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RISK FACTORS;

EID: 70350169224     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.98     Document Type: Review

References (44)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
3. Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of 11 cases: 1948. Cancer 82(1), 6-34 (1998).
4. Neglia JP, Robison LL, Stovall M et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl Cancer Inst. 98(21), 1528-1537 (2006). (Pubitemid 44680904)
5. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I. Longterm follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Rad. Res. 163, 424-432 (2005). (Pubitemid 40404651)
6. Karlsson P, Holmberg E, Lundell M, Mattsson A, Holm LE, Wallgren A. Intracranial tumors after exposure to ionizing radiation during infancy: a pooled analysis of two Swedish cohorts of 28,008 infants with skin hemangioma. Rad. Res. 150, 357-364 (1998). (Pubitemid 28397356)
7. Diallo I, Haddy N, Adjadj E et al. Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int. J. Rad. Biol. Phys. 74(3), 876-883 (2009).
8. Klein EE, Maserang B, Wood R, Mansur D. Peripheral doses from pediatric IMRT. Med. Phys. 33(7), 2525-2531 (2006).
9. Mansur DB, Klein EE, Maserang BP. Measured peripheral dose in pediatric radiation therapy: a comparison of intensitymodulated and conformal techniques. Radiother. Oncol. 82, 179-184 (2007).
10. Linet MS, Kim KP, Rajaraman P. Children's exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations. Pediatr. Radiol. 39(Suppl. 1), S4-S26 (2009).
11. Paulino AC, Mai WY, Chintagumpala M, Taher A. Radiation-induced malignant gliomas: is there a role for reirradiation. Int. J. Rad. Biol. Phys. 71(5), 1381-1387 (2008).
12. Cardis E, Vrijheid M, Blettner M et al. The 15-country collaborative study of cancer risk among radiation workers in the nuclear industry: estimates of radiation-related cancer risks. Rad. Res. 167, 396-416 (2007). (Pubitemid 351292970)
13. Yonehara S, Brenner AV, Kishikawa M et al. Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958-1995. Cancer 101(7), 1644-1654 (2004).
14. Rahu M, Rahu K, Anuvinen A et al. Cancer risk among Chernobyl cleanup workers from Estonia and Latvia, 1986-1998. Int. J. Cancer 119, 162-168 (2006).
15. Sodickson A, Baeyens PF, Andriole KP et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 251(1), 175-184 (2009).
16. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88(2), 398-406 (2000). (Pubitemid 30051826)
17. Boice JD Jr, Engholm G, Kleinerman RA et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat. Res. 116(1), 3-55 (1988). (Pubitemid 18278068)
18. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170(5), 1445-1453 (2007). (Pubitemid 47339290)
19. Brat DJ, James CD, Jedlicka AE et al. Molecular genetic alterations in radiationinduced astrocytomas. Am. J. Pathol. 154(5), 1431-1438 (1999).
20. Donson AM, Erwin NS, Kleinschmidt-DeMasters BK, Madden JR, Addo-Yobo SO, Foreman NK. Unique molecular characteristics of radiationinduced glioblastoma. J. Neuropath. Exp. Neurol. 66(8), 740-749 (2007).
21. Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 68(10), 3803-3809 (2008).
22. Wester MD, Wasteson A, Lindstrom A. Targeting malignant glioma cells in vitro using platelet-derived growth factor AA-based conjugates. J. Drug Target. 17(4), 268-277 (2009).
23. Ferletta M, Uhrbom L, Olofsson T, Ponten F, Westermark B. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-b-induced gliomagenesis. Mol. Cancer Res. 5(9), 891-897 (2007). (Pubitemid 47416666)
24. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 21(1), 109-122 (1991).
25. Mayer R, Sminia P. Reirradiation tolerance of the human brain. Int. J. Radiat. Oncol. Biol. Phys. 70(5), 1350-1360 (2008).
26. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
27. Schwer AL, Kavanagh BD, McCammon R et al. Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 73(5), 1352-1357 (2009).
28. Schwer AL, Damek DM, Kavanagh BD et al. A Phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 70(4), 993-1001 (2008).
29. Kohshi K, Yamamoto H, Nakahara A, Katoh T, Takagi M. Fractionated stereotactic radiotherapy using g unit after hyperbaric oxygenation on recurrent high-grade gliomas. J. Neurooncol. 82(3), 297-303 (2007). (Pubitemid 46614393)
30. Askins MA, Moore BD 3rd. Preventing neurocognitive late effects in childhood cancer survivors. J. Child Neurol. 23(10), 1160-1171 (2008).
31. Karachaliou F, Simatos G, Batika P, Michalacos S, Kaldrymides P. Endocrine consequences of childhood malignancies. J. BUON 14(1), 27-32 (2009).
32. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Biol. Phys. 65(1), 1-7 (2006).
33. Stern RL. Peripheral dose from a linear accelerator equipped with multileaf collimation. Med. Phys. 26(4), 559-563 (1999).
34. Robinson D, Scrimger JW, Field GC, Fallone BG. Shielding considerations for tomotherapy. Med. Phys. 27(10), 2380-2384 (2000).
35. Chibani O, Ma CM. Photonuclear dose calculations for high-energy photon beams from Siemens and Varian linacs. Med. Phys. 30(8), 1990-2000 (2003).
36. Fogliata A, Yartsev S, Nicolini G et al. On the performances of intensity modulated protons, RapidArc and helical tomotherapy for selected paediatric cases. Radiat. Oncol. 4, 2 (2009).
37. Howe GR, Burch JD, Chiarelli AM, Risch HA, Choi BC. An exploratory case- control study of brain tumors in children. Cancer Res. 49, 4349-4352 (1989).
38. McCredie M, Maisonneuve P, Boyle P. Perinatal and early postnatal risk factors for malignant brain tumors in New South Wales children. Int. J. Cancer 56, 11-15 (1994). (Pubitemid 24045799)
39. Shu XO, Jin F, Linet MS et al. Diagnostic x-ray and ultrasound exposure and risk in childhood cancer. Br. J. Cancer 70(3), 531-536 (1994). (Pubitemid 24268560)
40. Schuz J, Kaletsch U, Kaatsch P, Meinert R, Michaelis J. Risk factors for pediatric tumors of the central nervous system: results from a German population-based case-control study. Med. Pediatr. Oncol. 36, 274-282 (2001). (Pubitemid 32121312)
41. Kuijten RR, Bunin GR, Nass CC, Meadows AT. Gestational and familial risk factors for childhood astrocytoma: results of a case-control study. Cancer Res. 50, 2608-2612 (1990).
42. Bunin GR, Buckley JD, Boesel CP, Rorke LB, Meadows AT. Risk factors for astrocytic glioma and primitive neuroectodermal tumor of the brain in young children: a report from the Children's Cancer group. Cancer Epidemiol. Biomarkers Prev. 3, 197-204 (1994).
43. 2009 CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2005. Central Brain Tumor Registry of the United States www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS-NPCR2004- 2005-Report-.pdf
44. Phase II pilot study of adjuvant temozolomide concurrently with postoperative radiotherapy and then alone as maintenance therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, or diffuse intrinsic pontine glioma www.cancer.gov/clinicaltrials/ COGACNS0126